activated through a number of pathways in the hippocampus, but mechanisms regulating its activation in Aplysia during LTF are not well characterized. PKA is required for the translocation of ERK to the nucleus (Martin et al., 1997b), but neither PKA nor PKC are re- ing the kinase domain revealed that ApTrkl is most simi-5 Present address:
invertebrate LTrk is more similar to this family than is shown). K252a, a potent Trk kinase inhibitor, is also a potent inhibitor of ApTrkl ( Figure 1G ). This pharmacologApTrkl ( Figures 1B and 1C) . The Aplysia sequence includes the juxtamembrane NPxY signaling motif found ical profile is consistent with both the lack of homology between the extracellular region of ApTrkl and the Trks in mammalian Trk receptors. Despite the strong homology to Trks in the intracellular region, there was no and highly similar kinase domains. homology in the extracellular sequence to Trks or to other sequences in the database. We have thus named ApTrkl mRNA and Protein Are Present the receptor ApTrkl, which stands for "Aplysia Trk-like" in the Nervous System of Aplysia receptor. The initiating methionine is followed by a relaTo determine the expression pattern of ApTrkl in Aplysia, tively small ectodomain including two N-linked glycosylwe performed RT-PCR on various tissues. We found ation sites, a glycine-rich region, and a fragment of an the greatest expression of ApTrkl mRNA in the nervous EGF domain ( Figures 1A and 1D ). The ectodomain is system, as well as low-level expression in hepatopanfollowed by a single transmembrane region, a tyrosine creas, but not in other tissues (Figure 2A ). kinase domain, and a long C-terminal extension ending Western blotting using the E1 antibody in homogewith a putative PDZ recognition site ( Figure 1D ). Surprisnates of nervous system extracts revealed prominent ingly, there was not a clear signal peptide following ApTrkl protein expression ( Figure 2B ). We observed rethe initiating methionine, and extensive 5Ј RACE and activity with a 110 kDa antigen that comigrates with attempts to recover alternative splices have not revealed that seen in homogenized SF9 cell samples expressing an extended 5Ј end. The sequence on the N-terminal ApTrkl. In addition to the 110 kDa band, we also noted side of the putative transmembrane domain contains a reactivity with bands at 65 kDa, 160 kDa, and 180 kDa. net negative charge, while that on the C-terminal side The I1 and I2 antibodies also recognized the 110 kDa contains a net positive charge, suggesting the receptor band, but showed much greater cross-reactivity to other is a type-I transmembrane protein inserted into the proteins than did the anti-E1 antibody (data not shown). membrane in the correct orientation, with the C terminus
The anti-P1 antibody recognized a band at 90 kDa in inside (von Heijne, 1992). addition to the 110 kDa, 160 kDa, and 180 kDa bands ( Figure 2C ). Due to the cross-reactivity with multiple antibodies, we believe that the larger molecular weight Characterization of ApTrkl Proteins bands at 160 kDa and 180 kDa may be related receptors In order to characterize expression of ApTrkl, we raised or alternate splice variants. We have not determined antibodies (anti-I1, anti-I2, and anti-E1) to peptides detheir identity, and they will not be discussed further. The rived from intracellular (I1 and I2) and extracellular (E1) lower band at 66 kDa recognized by the anti-E1 antibody regions of the receptor. We also generated a phosphomay be a degradation product. The 90 kDa protein recpeptide-specific antibody (anti-P1) to the putative sigognized by anti-P1 is presumably another phosphorynaling tyrosine in the NPxY motif (P1) to monitor activalated protein containing an NPxY motif similar to that tion of the receptor. To test the antibodies, ApTrkl was of ApTrkl. expressed using baculovirus in SF9 cells. All antibodies, including anti-P1, immunoprecipitated a band of approximately 110 kDa, which is close to the predicted ApTrkl Is Expressed in Sensory Neurons Sensory neurons are the locus for the cellular memory molecular mass of the amino acid sequence (94 kDa) of the receptor ( Figure 1E) . A cross-reacting band of 100 underlying behavioral sensitization. To determine if ApTrkl was expressed in sensory neurons, we perkDa was also immunoprecipitated, but this band was also immunoprecipitated by preimmune sera. The 110 formed immunostaining on permeabilized and nonpermeabilized dissociated adult sensory neurons. ImmunokDa band recognized by the antibodies was also recognized by the anti-phosphotyrosine antibody 4g10. A kireactivity for ApTrkl was observed in both cell bodies and neurites ( Figures 2D and 2E ). Surface staining in nase-inactive (KR) mutant was not recognized by 4g10, demonstrating that ApTrkl expressed in SF9 cells has the nonpermeabilized samples showed punctate immunoreactivity for ApTrkl in cell bodies, as well as along the tyrosine kinase activity ( Figure 1F) . We also expressed a mutant with a Y-W mutation in the NPxY motif. This length of neurites. Thus, endogenous ApTrkl appears to be expressed on the cell surface in the correct orientamutant was not recognized by the anti-P1 antibody, despite immunoreactivity to 4g10 ( Figure 1F ). Immunotion, despite the lack of a signal peptide. As anti-E1 recognized multiple bands on Western reactivity to 4g10 is presumably due to phosphotyrosines present in the Trk kinase domain (Middlemas et blots, we needed to confirm that it was specific for ApTrkl in immunohistochemistry. To determine whether al., 1994) that are conserved in ApTrkl. The lack of P1 immunoreactivity shows specificity for the NPxY site this was the case, we knocked down expression of ApTrkl with RNA interference (RNAi). We injected either since the antiphosphopeptide antibody P1 did not recognize the active site phosphotyrosines recognized ApTrkl double-stranded RNA (dsRNA) or control dsRNA from another Aplysia RTK, Apror, into dissociated senby 4g10.
To investigate whether ApTrkl could be activated in sory neurons and then stained them 3 days later with the E1 antibody. Confocal microscopy showed a significant response to neurotrophins, we treated SF9 cells with commercially available neurotrophins and the tyrosine decrease in staining after ApTrkl dsRNA injection, but not after control dsRNA injection, indicating that the phosphatase inhibitor peroxyvanadium (pV). We found that treatment with pV strongly activated the receptor, anti-E1 antibody is largely specific for ApTrkl in sensory cells ( Figure 2F ). while the neurotrophins and serotonin had no effect on the receptor expressed in SF9 cells ( Figure 1G , data not
We also performed immunostaining on developmental (stage 11) animal nervous system whole mounts. Stainto a similar extent by each of these treatments ( Figure  3C , quantitated in Figure 3D ). Thus ApTrkl can be actiing was widespread and blocked by preincubating anti-E1 with E1 peptide ( Figure 2G ). In some experiments, vated by a 5 min exposure to 5-HT and is persistently activated during the entire length of the exposure to samples were also stained for sensorin, an Aplysia neuropeptide that is expressed exclusively in mechanosen-5-HT. sory neurons (Steffensen et al., 1995 Figure 3A , quantitreated with NT3, the TrkC ligand, homogenized, and tated in Figure 3B ). We found that pV strongly enhanced analyzed by Western blotting. Expression of the wildtyrosine phosphorylation, as detected by both antibodtype receptor led to an increase in ERK activation (pERK) ies. Furthermore, the pV-enhanced anti-P1 immunorebut had little effect on Akt phosphorylation (pAkt) (Figure activity was blocked by 100 nM K252a, suggesting that 4). Expression of the YW mutant chimera activated ERK, phosphorylation of the receptor following pV treatment but not to the same extent as the wild-type receptor, depends on its kinase activity ( Figure 3A , quantitated and had no effect on pAkt. Finally, expression of the KR in Figure 3B ). The inhibitor did not block all phosphorylamutant chimera had no effect on either pathway. These tion in the cell, since 4g10 staining was still apparent in results suggest that the chimera signals through the samples treated with pV plus K252a (data not shown;
NPxY as well as other signaling sites to activate ERK, also see Figure 6 ). To confirm the specificity of the antibut does not activate Akt. Treatment with NT3 induced P1 antibody in these experiments, we repeated the a further increase in pERK in the WT, but not in the YW knockdown of ApTrkl using RNAi and then treated the or KR chimeras, reaffirming that pERK signaling involves cells with pV ( Figure 3E ). We saw a large decrease in the NPxY site. In control experiments NT3 strongly actianti-P1 staining after ApTrkl dsRNA injection, but not vated both pERK and Akt when cells were transfected after Apror dsRNA injection, suggesting that this antiwith TrkC, suggesting that the specificity of ApTrkl is not body is specific for activated ApTrkl. RNAi did not affect due to properties of 
Endogenous ApTrkl Is Required for ERK
ited with 100 nM K252a, indicating that pV activates ERK partly through ApTrkl. In contrast, 4g10 staining Activation in Sensory Neurons Because ApTrkl is expressed in sensory neurons, we induced by pV was not significantly decreased by K252a, suggesting that the antagonist is not inhibiting were interested in testing whether the endogenous receptor could activate ERK. First, we activated the recepthe majority of tyrosine kinases in sensory cells. RNAi knockdown experiments were also performed to examtor with pV and saw robust activation of ERK ( Figures  6A and 6B) . This activation could be significantly inhibine the specificity of this effect. Indeed, pV caused signif- Figures 6E and 6F) , and this increase was blocked by K252a. We repeated ments using dsRNA. Injections of dsRNA had no effect on either the size of basal EPSPs or on the effects of these experiments using dsRNA injections of ApTrkl to remove the receptor. After removal of ApTrkl by dsRNA, control applications ( Figure 7D ). Thus, for statistical tests, the control applications for the three conditions 5-HT no longer significantly increased p-ERK levels in sensory neurons (Figures 6G and 6H) . In contrast, 5-HT were pooled. Decreasing the level of ApTrkl with dsRNA completely blocked LTF when induced by somatic applidid activate ERK when dsRNA encoding Apror was injected into sensory neurons (Figures 6G and 6H) . The cation of 5-HT, while the dsRNA to Apror had no effect on LTF induced by somatic application ( Figure 7E 
